SCI Abstract

search
+
The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines
Cocciolo, R., Turella, P., Pilunni, D., & Navarra, P. (2025). The length of price&reimbursement negotiation pro...
What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe
Solà-Morales, O., Lipska, I., Meyer, F., Canonico, P.-L., & Altmann, H. (2025). What is needed to successfully impl...
Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respira...
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
Cutrera R, Wolfler A, Picone S, et al. Impact of the 2014 American Academy of Pediatrics recommendat...
Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices
Goodland R. The Concept of Environmental Sustainability. Annu Rev Ecol Syst. 1995;26(1):1-24. https:...
Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel
Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven Europea...
Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity Vitamin and ...
Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):6...
HTA regulation: how is Italy moving?
Authors Francesca Patarnello Vice-President Market Access ...
Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis
Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moder...
Regional Formularies in Italy: current state and future perspectives
Jommi C, Pippo L, Bortolami A et al. Il governo dell’assistenza farmaceutica in Italia: il ruolo di ...
The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example
Vos T, Lim SS, Abbafati C, et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369...
The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ...
Heart failure and economic impact: an analysis in real clinical practice in Italy
Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ. 2000;32...
Regional administrative data and their role in planning, programming and controlling at regional level
Marzona, I., Stella, P., Trifirò, G., & Corrao, G. (2024). Regional administrative data and their role in planning,...
Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy
Messori, A., Romeo, M. R., Fadda, V., Collini, F., & Trippoli, S. (2024). Costs and benefits in patients with NYHA ...
Patient-reported outcomes in epilepsy: a case study exploring their usage and impact
Food and Drug Administration. U.S. Department of Health and Human Services. Patient-Reported Outcome...
The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service
Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real-world data: an overvi...
Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders
Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome – reviewing challenges in diagnosis and trea...
How effective are prescriptive governance tools? Results from the application of AIFA notes
Agenzia Italiana del Farmaco (AIFA). Note AIFA | [Internet]. (Accessed September 2023) Online: https...
Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascu...
Early access programs for medicines: a reform proposal for the Italian National Health Service
Popoli, P., Giuliani, G., Cavaliere, A., & Jommi, C. (2024). Early access programs for medicines: a reform proposal...
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy
Erickson SM, Rockwern B, Koltov M, McLean RM; Medical Practice and Quality Committee of the American...
Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France 2020: https:/...
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new...
Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)
Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and p...
The future of drugs distribution in the National Health System
Medaglia, M., Buzzetti, G., Cossolo, M., Deambrosis, P., & Scroccaro, G. (2024). The future of drugs distribution i...
Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis
Robertson I, Leung E, Hughes D, et al. Prospective analysis of stoma-related complications. Colorect...
Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. https://doi.o...
Time to market access in Italy: duration of the P&R process for rare disease drugs
Kwon HY, Kim H, Godman B. Availability and Affordability of Drugs With a Conditional Approval by the...
Load More
format_indent_increase